117 related articles for article (PubMed ID: 37220080)
21. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
24. Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.
Czajka AA; Wójcicka A; Kubiak A; Kotlarek M; Bakuła-Zalewska E; Koperski Ł; Wiechno W; Jażdżewski K
PLoS One; 2016; 11(3):e0151968. PubMed ID: 27011326
[TBL] [Abstract][Full Text] [Related]
25. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
26. Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1α and microRNA-146a.
Long M; Zhu Y; Chen Z; Lin S; Peng X; Luo D; Li H; Tan L
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32303750
[TBL] [Abstract][Full Text] [Related]
27. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
28. Chromatin-Accessible miRNA Regulons Driving Thyroid Tumorigenesis and Progression.
Toraih EA; Ruiz E; Ning B; Tortelote GG; Hilliard S; Moroz K; Hu T; Fawzy MS; Kandil E
J Am Coll Surg; 2023 Apr; 236(4):732-750. PubMed ID: 36728308
[TBL] [Abstract][Full Text] [Related]
29. Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.
Ortiz IMDP; Barros-Filho MC; Dos Reis MB; Beltrami CM; Marchi FA; Kuasne H; do Canto LM; de Mello JBH; Abildgaard C; Pinto CAL; Kowalski LP; Rogatto SR
Clin Epigenetics; 2018 Nov; 10(1):144. PubMed ID: 30454026
[TBL] [Abstract][Full Text] [Related]
30. Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.
Peng Y; Li C; Luo DC; Ding JW; Zhang W; Pan G
Molecules; 2014 Aug; 19(8):11586-99. PubMed ID: 25100252
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
Wu YC; Li SY; Jia YF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2.
Fu YT; Zheng HB; Zhang DQ; Zhou L; Sun H
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3430-3438. PubMed ID: 29917195
[TBL] [Abstract][Full Text] [Related]
33. Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC).
Jazdzewski K; Boguslawska J; Jendrzejewski J; Liyanarachchi S; Pachucki J; Wardyn KA; Nauman A; de la Chapelle A
J Clin Endocrinol Metab; 2011 Mar; 96(3):E546-53. PubMed ID: 21159845
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma.
Chen YT; Kitabayashi N; Zhou XK; Fahey TJ; Scognamiglio T
Mod Pathol; 2008 Sep; 21(9):1139-46. PubMed ID: 18587330
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation.
Celakovsky P; Kovarikova H; Chrobok V; Mejzlik J; Laco J; Vosmikova H; Chmelarova M; Ryska A
In Vivo; 2021; 35(1):319-323. PubMed ID: 33402480
[TBL] [Abstract][Full Text] [Related]
36. MiR-506 suppresses papillary thyroid carcinoma cell proliferation and metastasis via targeting IL17RD.
Zhu J; Zhang Q; Jin XY; Cai JB; Chen X; Shi WB; Pang WY; Guo GL; Yang LJ
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2856-2862. PubMed ID: 31002136
[TBL] [Abstract][Full Text] [Related]
37. miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma.
Lv M; Zhang X; Li M; Chen Q; Ye M; Liang W; Ding L; Cai H; Fu D; Lv Z
PLoS One; 2013; 8(7):e67591. PubMed ID: 23861775
[TBL] [Abstract][Full Text] [Related]
38. MiR-4500 Regulates PLXNC1 and Inhibits Papillary Thyroid Cancer Progression.
Li R; Teng X; Zhu H; Han T; Liu Q
Horm Cancer; 2019 Dec; 10(4-6):150-160. PubMed ID: 31317324
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
Wang Z; Zhang H; Zhang P; Dong W; He L
Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
[TBL] [Abstract][Full Text] [Related]
40. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
